成人偏头痛急性发作药物干预效果比较:系统评价与网络Meta分析
该系统评价与网络Meta分析纳入137项双盲随机对照试验、89445例成人偏头痛患者,比较17种口服单药急性治疗与安慰剂的疗效。所有活性药物在2小时无痛方面均优于安慰剂,依曲普坦在头对头比较中疗效最佳。作者认为依曲普坦、利扎曲普坦、舒马曲普坦和佐米曲普坦最具优势,建议将最有效的曲普坦类作为首选急性治疗并纳入WHO基本药物目录。
要点
- 所有活性药物在2小时无痛方面均优于安慰剂,OR从1.73(那拉曲普坦)到5.19(依曲普坦)。
- 头对头比较中依曲普坦2小时无痛疗效最佳,其次为利扎曲普坦、舒马曲普坦和佐米曲普坦。
- 依曲普坦和布洛芬在持续无痛至24小时方面疗效最佳,OR从1.41到4.82。
核心结论
- 依曲普坦、利扎曲普坦、舒马曲普坦和佐米曲普坦总体表现最佳,疗效优于近期上市的拉米地坦、瑞美吉泮和乌布吉泮。
- 作者认为最有效的曲普坦类应考虑作为偏头痛首选急性治疗,并纳入WHO基本药物目录以促进全球可及性和统一诊疗标准。
- 作者指出需进行成本效果分析,并对心血管高危患者给予审慎考虑。
研究设计与样本
- 系统评价与网络Meta分析,检索Cochrane对照试验中心注册库、Medline、Embase、ClinicalTrials.gov、欧盟临床试验注册库、WHO国际临床试验注册平台及监管机构和制药公司网站,截至2023年6月24日,无语言限制。
- 纳入137项双盲随机对照试验,共89445例成人(≥18岁)偏头痛患者,按国际头痛疾病分类诊断,分配至17种活性干预或安慰剂。
- 采用随机效应网络Meta分析,主要结局为服药后2小时无痛比例和2至24小时持续无痛比例,均未使用补救药物。
- 证据确定性采用CINeMA在线工具分级,使用Vitruvian图总结发现,由国际临床医生和偏头痛亲历者小组共同设计研究并解读结果。
主要发现
- 所有活性干预在2小时无痛方面均优于安慰剂,OR从1.73(95%CI 1.27至2.34,那拉曲普坦)到5.19(95%CI 4.25至6.33,依曲普坦)。
- 大多数活性干预在持续无痛至24小时方面优于安慰剂,OR从1.71(95%CI 1.07至2.74,塞来昔布)到7.58(95%CI 2.58至22.27,布洛芬)。
- 头对头比较中,依曲普坦为2小时无痛最有效药物(OR从1.46(95%CI 1.18至1.81)到3.01(95%CI 2.13至4.25)),其次为利扎曲普坦(OR从1.59(95%CI 1.18至2.17)到2.44(95%CI 1.75至3.45))、舒马曲普坦(OR从1.35(95%CI 1.03至1.75)到2.04(95%CI 1.49至2.86))和佐米曲普坦(OR从1.47(95%CI 1.04至2.08)到1.96(95%CI 1.39至2.86))。
- 持续无痛方面最有效的干预为依曲普坦和布洛芬(OR从1.41(95%CI 1.02至1.93)到4.82(95%CI 1.31至17.67))。
- CINeMA证据确定性从高到极低不等;仅限FDA批准剂量的敏感性分析、高剂量与低剂量比较、偏倚风险分析以及基线中重度头痛的敏感性分析均证实主要和次要结局的主要发现。
临床怎么用
- 作者认为最有效的曲普坦类应考虑作为偏头痛首选急性治疗,并纳入WHO基本药物目录以促进全球可及性和统一诊疗标准。
- 作者指出需进行成本效果分析,并对心血管高危患者给予审慎考虑。
局限性
- CINeMA证据确定性从高到极低不等。
- 作者指出需进行成本效果分析。
- 作者指出应对心血管高危患者给予审慎考虑。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare all licensed drug interventions as oral monotherapy for the acute treatment of migraine episodes in adults. DESIGN: Systematic review and network meta-analysis. DATA SOURCES: Cochrane Central Register of Controlled Trials, Medline, Embase, ClinicalTrials.gov, EU Clinical Trials Register, WHO International Clinical Trials Registry Platform, as well as websites of regulatory agencies and pharmaceutical companies without language restrictions until 24 June 2023. METHODS: Screening, data extraction, coding, and risk of bias assessment were performed independently and in duplicate. Random effects network meta-analyses were conducted for the primary analyses. The primary outcomes were the proportion of participants who were pain-free at two hours post-dose and the proportion of participants with sustained pain freedom from two to 24 hours post-dose, both without the use of rescue drugs. Certainty of the evidence was graded using the confidence in network meta-analysis (CINeMA) online tool. Vitruvian plots were used to summarise findings. An international panel of clinicians and people with lived experience of migraine co-designed the study and interpreted the findings. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Double blind randomised trials of adults (≥18 years) with a diagnosis of migraine according to the International Classification of Headache Disorders. RESULTS: 137 randomised controlled trials comprising 89 445 participants allocated to one of 17 active interventions or placebo were included. All active interventions showed superior efficacy compared with placebo for pain freedom at two hours (odds ratios from 1.73 (95% confidence interval (CI) 1.27 to 2.34) for naratriptan to 5.19 (4.25 to 6.33) for eletriptan), and most of them also for sustained pain freedom to 24 hours (odds ratios from 1.71 (1.07 to 2.74) for celecoxib to 7.58 (2.58 to 22.27) for ibuprofen). In head-to-head comparisons between active interventions, eletriptan was the most effective drug for pain freedom at two hours (odds ratios from 1.46 (1.18 to 1.81) to 3.01 (2.13 to 4.25)), followed by rizatriptan (1.59 (1.18 to 2.17) to 2.44 (1.75 to 3.45)), sumatriptan (1.35 (1.03 to 1.75) to 2.04 (1.49 to 2.86)), and zolmitriptan (1.47 (1.04 to 2.08) to 1.96 (1.39 to 2.86)). For sustained pain freedom, the most efficacious interventions were eletriptan and ibuprofen (odds ratios from 1.41 (1.02 to 1.93) to 4.82 (1.31 to 17.67)). Confidence in accordance with CINeMA ranged from high to very low. Sensitivity analyses on Food and Drug Administration licensed doses only, high versus low doses, risk of bias, and moderate to severe headache at baseline confirmed the main findings for both primary and secondary outcomes. CONCLUSIONS: Overall, eletriptan, rizatriptan, sumatriptan, and zolmitriptan had the best profiles and they were more efficacious than the recently marketed drugs lasmiditan, rimegepant, and ubrogepant. Although cost effectiveness analyses are warranted and careful consideration should be given to patients with a high risk cardiovascular profile, the most effective triptans should be considered as preferred acute treatment for migraine and included in the WHO List of Essential Medicines to promote global accessibility and uniform standards of care. SYSTEMATIC REVIEW REGISTRATION: Open Science Framework https://osf.io/kq3ys/.
引用
- Karlsson WK, Ostinelli EG, Zhuang ZA, et al. Comparative effects of drug interventions for the acute management of migraine episodes in adults: systematic review and network meta-analysis. BMJ. 2024. PMID: 39293828. doi:10.1136/bmj-2024-080107
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。